ZUMA-23: A phase 3 trial of axicabtagene ciloleucel in people with high-risk large B-cell lymphoma
This trial is testing the CAR-T cell therapy axicabtagene ciloleucel in people with high-risk large B-cell lymphoma as first line therapy.
You can share the following ClinicalTrials.gov Identifier with your medical team so they can find out more about the trial: NCT05605899
Trial aim and background
The aim of this trial is to find out how effective the medication axicabtagene ciloleucel is when compared to standard of care in people with high-risk large B-cell lymphoma.
People will be monitored for 5 years and then transferred to a separate long-term follow-up study (study KT-US-982-5968) to complete 15 years of assessments.
Axicabtagene ciloleucel is a form of CAR-T cell therapy. CAR-T cell therapy uses cells from your own immune system to fight the lymphoma.
Who can enter
People with diffuse large B-cell lymphoma (DLBCL) or other high-grade B-cell lymphoma (HGBL) may be eligible for this trial. People with marginal cell lymphoma or follicular lymphoma which has transformed into DLBCL may also be eligible.
Locations
Recruitment is taking place in the following UK locations:
- Addenbrookes Hospital, Cambridge
- University Hospitals, Southampton
Further information
More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://clinicaltrials.gov/study/NCT05605899
Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.